| Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid MA Dimopoulos, E Kastritis, C Bamia, I Melakopoulos, D Gika, M Roussou, ... Annals of Oncology 20 (1), 117-120, 2009 | 577 | 2009 |
| Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the … E Kastritis, K Zervas, A Symeonidis, E Terpos, S Delimbassi, ... Leukemia 23 (6), 1152-1157, 2009 | 239 | 2009 |
| Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone E Kastritis, A Anagnostopoulos, M Roussou, S Toumanidis, C Pamboukas, ... Haematologica 92 (10), 1351-1358, 2007 | 233 | 2007 |
| Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents E Kastritis, A Anagnostopoulos, M Roussou, D Gika, C Matsouka, ... haematologica 92 (4), 546-549, 2007 | 207 | 2007 |
| Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease E Kastritis, E Terpos, L Moulopoulos, M Spyropoulou-Vlachou, ... Leukemia 27 (4), 947-953, 2013 | 199 | 2013 |
| The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma MA Dimopoulos, M Roussou, M Gkotzamanidou, N Nikitas, E Psimenou, ... Leukemia 27 (2), 423-429, 2013 | 196 | 2013 |
| High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents E Terpos, E Katodritou, M Roussou, A Pouli, E Michalis, S Delimpasi, ... European journal of haematology 85 (2), 114-119, 2010 | 158 | 2010 |
| Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors MA Dimopoulos, M Roussou, M Gavriatopoulou, F Zagouri, M Migkou, ... Clinical Lymphoma and Myeloma 9 (4), 302-306, 2009 | 158 | 2009 |
| Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of … MA Dimopoulos, E Kastritis, D Christoulas, M Migkou, M Gavriatopoulou, ... Leukemia 24 (10), 1769-1778, 2010 | 148 | 2010 |
| The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement … E Terpos, E Kastritis, M Roussou, D Heath, D Christoulas, ... Leukemia 22 (12), 2247-2256, 2008 | 142 | 2008 |
| Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study E Kastritis, M Gavriatopoulou, MC Kyrtsonis, M Roussou, E Hadjiharissi, ... Blood, The Journal of the American Society of Hematology 126 (11), 1392-1394, 2015 | 133 | 2015 |
| The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment E Terpos, M Gavriatopoulou, I Ntanasis-Stathopoulos, A Briasoulis, ... Blood Cancer Journal 11 (8), 138, 2021 | 127 | 2021 |
| A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis E Kastritis, E Terpos, M Roussou, M Gavriatopoulou, C Pamboukas, ... Blood, The Journal of the American Society of Hematology 119 (23), 5384-5390, 2012 | 118 | 2012 |
| Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens M Roussou, E Kastritis, M Migkou, E Psimenou, I Grapsa, C Matsouka, ... Leukemia & lymphoma 49 (5), 890-895, 2008 | 113 | 2008 |
| Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents M Roussou, E Kastritis, D Christoulas, M Migkou, M Gavriatopoulou, ... Leukemia research 34 (10), 1395-1397, 2010 | 111 | 2010 |
| Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients … LA Moulopoulos, MA Dimopoulos, E Kastritis, D Christoulas, ... American journal of hematology 87 (9), 861-864, 2012 | 109 | 2012 |
| Cardiac and renal complications of carfilzomib in patients with multiple myeloma MA Dimopoulos, M Roussou, M Gavriatopoulou, E Psimenou, D Ziogas, ... Blood advances 1 (7), 449-454, 2017 | 101 | 2017 |
| Bortezomib‐based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure … MA Dimopoulos, M Roussou, M Gavriatopoulou, E Psimenou, ... American journal of hematology 91 (5), 499-502, 2016 | 101 | 2016 |
| Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma E Kastritis, E Terpos, M Roussou, M Gavriatopoulou, M Migkou, ... Haematologica 102 (3), 593, 2017 | 94 | 2017 |
| Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment MA Dimopoulos, D Christoulas, M Roussou, E Kastritis, M Migkou, ... European journal of haematology 85 (1), 1-5, 2010 | 89 | 2010 |
